

# Scott P Kelly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2574209/publications.pdf>

Version: 2024-02-01

52  
papers

2,944  
citations

236612

25  
h-index

214527

47  
g-index

52  
all docs

52  
docs citations

52  
times ranked

5375  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. <i>Ophthalmology</i> , 2021, 128, 910-919.	2.5	29
2	Fatherhood status in relation to prostate cancer risks in two large U.S.-based prospective cohort studies. <i>Cancer Medicine</i> , 2021, 10, 405-415.	1.3	0
3	The Tube Versus Trabeculectomy IRIS <sup>®</sup> Registry Study: Cohort Selection and Follow-up and Comparisons to the Randomized Controlled Trial. <i>American Journal of Ophthalmology</i> , 2021, 224, 43-52.	1.7	10
4	Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy. <i>Diabetes Care</i> , 2021, 44, 748-756.	4.3	59
5	Factors Associated With Favorable Laser Trabeculoplasty Response: IRIS Registry Analysis. <i>American Journal of Ophthalmology</i> , 2021, 223, 149-158.	1.7	9
6	Tube Versus Trabeculectomy IRIS <sup>®</sup> Registry 1-Year Composite Outcome Analysis with Comparisons to the Randomized Controlled Trial. <i>American Journal of Ophthalmology</i> , 2021, 227, 87-99.	1.7	7
7	Reply to Comment on: The Tube Versus Trabeculectomy IRIS <sup>®</sup> Registry Study: Cohort Selection and Follow-up and Comparisons to the Randomized Controlled Trial. <i>American Journal of Ophthalmology</i> , 2021, 227, 284-286.	1.7	0
8	Factors Associated With Laser Trabeculoplasty Response Duration: Analysis of a Large Clinical Database (IRIS Registry). <i>Journal of Glaucoma</i> , 2021, 30, 902-910.	0.8	6
9	Clinical Outcomes of Rhegmatogenous Retinal Detachment Treated With Pneumatic Retinopexy. <i>JAMA Ophthalmology</i> , 2021, 139, 848.	1.4	12
10	Demographic and Clinical Characteristics Associated with Minimally Invasive Glaucoma Surgery Use. <i>Ophthalmology</i> , 2021, 128, 1292-1299.	2.5	19
11	Endophthalmitis after Cataract Surgery in the United States. <i>Ophthalmology</i> , 2020, 127, 151-158.	2.5	115
12	Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 177-185.	1.1	8
13	Return to the Operating Room for Removal of Retained Lens Fragments after Cataract Surgery: IRIS <sup>®</sup> Registry (Intelligent Research in Sight) Analysis. <i>Ophthalmology</i> , 2020, 127, 698-699.	2.5	6
14	Overall and abdominal obesity and prostate cancer risk in a West African population: An analysis of the Ghana Prostate Study. <i>International Journal of Cancer</i> , 2020, 147, 2669-2676.	2.3	7
15	Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment. <i>British Journal of Cancer</i> , 2020, 123, 487-494.	2.9	17
16	Ophthalmic immune-related adverse events following anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology IRIS Registry. <i>Journal of Clinical Oncology</i> , 2020, 38, e15124-e15124.	0.8	1
17	Association of Leisure-Time Physical Activity Across the Adult Life Course With All-Cause and Cause-Specific Mortality. <i>JAMA Network Open</i> , 2019, 2, e190355.	2.8	136
18	A population-based study of cardiovascular disease mortality risk in US cancer patients. <i>European Heart Journal</i> , 2019, 40, 3889-3897.	1.0	501

#	ARTICLE	IF	CITATIONS
19	Changing Landscape of Liver Cancer in California: A Glimpse Into the Future of Liver Cancer in the United States. <i>Journal of the National Cancer Institute</i> , 2019, 111, 550-556.	3.0	13
20	Body mass index trajectories across adulthood and smoking in relation to prostate cancer risks: the NIH-AARP Diet and Health Study. <i>International Journal of Epidemiology</i> , 2019, 48, 464-473.	0.9	26
21	Usual adult occupation and risk of prostate cancer in West African men: the Ghana Prostate Study. <i>Occupational and Environmental Medicine</i> , 2019, 76, 71-77.	1.3	8
22	Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 517-524.	1.1	13
23	Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States. <i>European Urology Focus</i> , 2018, 4, 121-127.	1.6	162
24	Breast cancer in Portugal: Temporal trends and age-specific incidence by geographic regions. <i>Cancer Epidemiology</i> , 2018, 54, 12-18.	0.8	11
25	Framework to construct and interpret latent class trajectory modelling. <i>BMJ Open</i> , 2018, 8, e020683.	0.8	149
26	Abstract 5246: Lifetime trajectories of cigarette smoking and cancer mortality among older adults in a large cohort in the United States. , 2018, , .		0
27	Future of testicular germ cell tumor incidence in the United States: Forecast through 2026. <i>Cancer</i> , 2017, 123, 2320-2328.	2.0	82
28	Body weight trajectories and risk of oesophageal and gastric cardia adenocarcinomas: a pooled analysis of NIH-AARP and PLCO Studies. <i>British Journal of Cancer</i> , 2017, 116, 951-959.	2.9	40
29	Adiposity across the adult life course and incidence of primary liver cancer: The NIH-AARP cohort. <i>International Journal of Cancer</i> , 2017, 141, 271-278.	2.3	34
30	Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw225.	3.0	62
31	Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. <i>European Urology</i> , 2017, 71, 195-201.	0.9	77
32	Sex Steroid Hormone Single-Nucleotide Polymorphisms, Pesticide Use, and the Risk of Prostate Cancer: A Nested Case-Control Study within the Agricultural Health Study. <i>Frontiers in Oncology</i> , 2016, 6, 237.	1.3	5
33	Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. <i>Journal of Clinical Oncology</i> , 2016, 34, 1787-1794.	0.8	346
34	Sociodemographic and Clinical Predictors of Switching to Active Treatment among a Large, Ethnically Diverse Cohort of Men with Low Risk Prostate Cancer on Observational Management. <i>Journal of Urology</i> , 2016, 196, 734-740.	0.2	11
35	Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1240-1250.	1.1	32
36	Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast/ovarian cancer. <i>Familial Cancer</i> , 2016, 15, 529-539.	0.9	22

#	ARTICLE	IF	CITATIONS
37	Patient Perceptions of Telephone vs. In-Person <i>BRCA1/BRCA2</i> Genetic Counseling. <i>Journal of Genetic Counseling</i> , 2016, 25, 472-482.	0.9	46
38	Abstract 5208: Trends in fatal prostate cancer incidence by race among US men. , 2016, , .		0
39	Disparities in Uptake of BRCA1/2 Genetic Testing in a Randomized Trial of Telephone Counseling. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 614-616.	0.2	0
40	Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. <i>Genetics in Medicine</i> , 2015, 17, 467-475.	1.1	86
41	Decisional outcomes following use of an interactive web-based decision aid for prostate cancer screening. <i>Translational Behavioral Medicine</i> , 2015, 5, 189-197.	1.2	8
42	Consumption of caffeinated and artificially sweetened soft drinks is associated with risk of early menarche. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 648-654.	2.2	50
43	Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. <i>Psycho-Oncology</i> , 2015, 24, 33-39.	1.0	28
44	The Association of Long-term Treatment-related Side Effects With Cancer-specific and General Quality of Life Among Prostate Cancer Survivors. <i>Urology</i> , 2014, 84, 300-306.	0.5	53
45	Randomized Noninferiority Trial of Telephone Versus In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 618-626.	0.8	226
46	Decision Making in Prostate Cancer Screening Using Decision Aids vs Usual Care. <i>JAMA Internal Medicine</i> , 2013, 173, 1704-12.	2.6	61
47	Monitoring of health-related quality of life and symptoms in prostate cancer survivors: a randomized trial. <i>The Journal of Supportive Oncology</i> , 2013, 11, 174-182.	2.3	12
48	Long-Term Disease-Specific Functioning Among Prostate Cancer Survivors and Noncancer Controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2768-2775.	0.8	67
49	Long-Term Psychosocial Outcomes of <i>BRCA1</i>/<i>BRCA2</i> Testing: Differences across Affected Status and Risk-Reducing Surgery Choice. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 445-455.	1.1	70
50	Through the lens of culture: quality of life among Latina breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 603-613.	1.1	63
51	Men's Use of an Internet-Based Decision Aid for Prostate Cancer Screening. <i>Journal of Health Communication</i> , 2012, 17, 677-697.	1.2	22
52	Long-term outcomes of <i>BRCA1/BRCA2</i> testing: risk reduction and surveillance. <i>Cancer</i> , 2012, 118, 510-517.	2.0	117